- Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals Endpoints News
- Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials Yahoo Finance
- Compass says its psilocybin drug helped patients with severe depression in two trials statnews.com
- Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push Fierce Biotech
- Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression Business Wire